Skip to main content
RCEL
NASDAQ Industrial Applications And Services

AVITA Medical Appoints Seasoned Healthcare Executive Joe Woody to Board of Directors

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
7
Price
$3.47
Mkt Cap
$105.811M
52W Low
$3.25
52W High
$14.16
Market data snapshot near publication time

summarizeSummary

AVITA Medical appointed Joe Woody, a seasoned healthcare executive and former CEO of Avanos Medical, to its Board of Directors, enhancing the company's strategic and operational expertise.


check_boxKey Events

  • New Director Appointment

    Joe Woody was appointed to the Board of Directors of AVITA Medical, Inc., effective January 1, 2026, and will serve on all Board committees.

  • Extensive Healthcare Experience

    Mr. Woody brings over two decades of leadership experience in the medical technology sector, including prior roles as CEO of Avanos Medical and President and CEO of Acelity Holdings.

  • Director Compensation

    Mr. Woody will receive an annual cash retainer of $92,500 and an initial equity grant valued at $210,000, comprising stock options and restricted stock units, subject to shareholder approval.

  • Chairman Retirement

    Lou Panaccio, who served as Chairman from July 2014 to August 2025, retired from the Board of Directors.


auto_awesomeAnalysis

AVITA Medical has strengthened its Board of Directors with the appointment of Joe Woody, a highly experienced executive from the medical technology sector. Mr. Woody's extensive background, including his tenure as CEO of Avanos Medical and President and CEO of Acelity Holdings, is expected to bring valuable strategic and operational insights to the company. This move is a positive development for AVITA Medical's governance and future strategic direction. Concurrently, long-serving Chairman Lou Panaccio retired, marking a transition in board leadership.

At the time of this filing, RCEL was trading at $3.47 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $105.8M. The 52-week trading range was $3.25 to $14.16. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed RCEL - Latest Insights

RCEL
Apr 22, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
8
RCEL
Apr 14, 2026, 7:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
RCEL
Apr 08, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
8
RCEL
Apr 08, 2026, 4:10 PM EDT
Source: GlobeNewswire
Importance Score:
7
RCEL
Mar 31, 2026, 4:54 PM EDT
Filing Type: S-3
Importance Score:
8
RCEL
Feb 12, 2026, 5:20 PM EST
Filing Type: 10-K
Importance Score:
9
RCEL
Feb 12, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
RCEL
Jan 13, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
RCEL
Jan 05, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
7